Long-term results of fludarabine/melphalan as a reduced-intensity conditioning regimen in mantle cell lymphoma: the GELTAMO experience | Zendy

Jorge Gayoso | Zendy; Rodrigo Martino | Zendy; Pascual Balsalobre | Zendy; Inmaculada Heras | Zendy; José Luís Piñana | Zendy; David Serrano | Zendy; Javier de la Serna | Zendy; José Francisco Tomás | Zendy; José L. DíezMartín | Zendy; Dolores Caballero | Zendy

Open Access

Long-term results of fludarabine/melphalan as a reduced-intensity conditioning regimen in mantle cell lymphoma: the GELTAMO experience

Author(s) -

Jorge Gayoso,

Rodrigo Martino,

Pascual Balsalobre,

Inmaculada Heras,

José Luís Piñana,

David Serrano,

Javier de la Serna,

José Francisco Tomás,

José L. DíezMartín,

Dolores Caballero

Publication year - 2011

Publication title -

therapeutic advances in hematology

Language(s) - English

Resource type - Journals

eISSN - 2040-6215

pISSN - 2040-6207

DOI - 10.1177/2040620710396752

Subject(s) - medicine , fludarabine , melphalan , mucositis , mantle cell lymphoma , neutropenia , gastroenterology , cumulative incidence , surgery , hematopoietic stem cell transplantation , lymphoma , multiple myeloma , chemotherapy , transplantation , cyclophosphamide

We herein report the long-term results of an allogeneic reduced-intensity conditioning (allo-RIC) protocol used in 21 consecutive patients (16 males, median age 56 years, 71% in complete remission) diagnosed with mantle cell lymphoma (MCL).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research